期刊文献+
共找到6篇文章
< 1 >
每页显示 20 50 100
免疫检查点抑制剂在驱动基因阳性晚期非小细胞肺癌中的应用进展 被引量:3
1
作者 张同梅(综述) 李宝兰(审校) 《中国肺癌杂志》 CAS CSCD 北大核心 2021年第3期188-195,共8页
随着肿瘤精准医学的发展,驱动基因阳性非小细胞肺癌(non-small cell lung cancer,NSCLC)患者接受靶向治疗极大地改善了生存和预后,但不管是哪代靶向药物均不可避免的会经历耐药,患者会面临无靶可用的局面。免疫检查点抑制剂因其特有的... 随着肿瘤精准医学的发展,驱动基因阳性非小细胞肺癌(non-small cell lung cancer,NSCLC)患者接受靶向治疗极大地改善了生存和预后,但不管是哪代靶向药物均不可避免的会经历耐药,患者会面临无靶可用的局面。免疫检查点抑制剂因其特有的长拖尾效应,能给部分晚期NSCLC患者带来长生存。越来越多的研究显示免疫治疗同样可为部分驱动基因阳性NSCLC患者带来获益,但免疫治疗介入的时机、治疗方案的选择以及预测生物标记物等问题仍不十分明确,值得进一步探讨。 展开更多
关键词 肺肿瘤 驱动基因 免疫检查点抑制剂 预测
下载PDF
单中心晚期非小细胞肺癌免疫治疗真实世界数据分析 被引量:6
2
作者 刘艳霞 张同梅 +7 位作者 高远 曲阳 鲁葆华 张红梅 王群慧 李杰 胡范彬 李宝兰 《中国肺癌杂志》 CAS CSCD 北大核心 2019年第11期687-695,共9页
背景与目的近些年,多项临床试验显示免疫检查点抑制剂(immunocheckpoint inhibitor,ICI)为晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)患者带来生存获益,但临床试验有着严格而复杂的纳入与排除标准,其结果不能完全反映真实世... 背景与目的近些年,多项临床试验显示免疫检查点抑制剂(immunocheckpoint inhibitor,ICI)为晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)患者带来生存获益,但临床试验有着严格而复杂的纳入与排除标准,其结果不能完全反映真实世界的实际情况。本研究拟探讨真实世界中免疫治疗的临床疗效和安全性以及可能相关的预后因素。方法回顾性分析2017年1月-2019年7月在北京胸科医院接受免疫治疗的晚期NSCLC患者,收集患者基本临床资料、治疗疗效、无进展生存期(progression-free survival,PFS)和药物不良反应等资料,探讨临床疗效、不良反应及可能相关的预后因素。结果研究共纳入34例患者,中位PFS为5.66个月(95%CI:4.48个月-6.84个月),1级-2级不良反应和3级-4级不良反应发生率分别为61.71%(22/34)和14.71%(5/34),共有3例(8.82%)患者出现致死性免疫相关不良反应(immune-related adverse event,ir AE),其中2例为免疫相关肺炎,1例为免疫相关心肌炎。单因素分析显示肿瘤-淋巴结-转移(tumor-node-metastasis,TNM)分期、转移部位与中位PFS相关(P<0.05),多因素分析显示存在肺外转移(OR=6.42,P=0.029)、胸膜转移(OR=14.14,P=0.006)为患者PFS的独立预后因素。结论真实世界中免疫治疗对晚期NSCLC患者具有良好的疗效,但其严重ir AE的发生率也较高。存在肺外转移、胸膜转移是接受免疫治疗的晚期NSCLC患者的不良预后因素。 展开更多
关键词 肺肿瘤 免疫治疗 临床疗效 不良反应
下载PDF
The expression of vascular endothelial growth factor(VEGF)/endostatin(ES)and VEGF receptor 2(VEGFR2)/ES is associated with NSCLC prognosis 被引量:2
3
作者 Yuan Yang Baohua Lu +5 位作者 Baolan Li Weiying Li Mei Jiang Wentao Yue Qunhui Wang tongmei zhang 《Oncology and Translational Medicine》 CAS 2021年第4期149-154,共6页
Objective The aim of our study was to detect the expression of angiogenesis inhibitory proteins and angiogenesis promotive proteins in the postoperative tumor tissue of non-small cell lung cancer(NSCLC)patients.We als... Objective The aim of our study was to detect the expression of angiogenesis inhibitory proteins and angiogenesis promotive proteins in the postoperative tumor tissue of non-small cell lung cancer(NSCLC)patients.We also investigated the relationship of protein expression with clinical characteristics and prognosis.Methods We examined the expression of vascular endothelial growth factor(VEGF),VEGF receptor 2(VEGFR2),and endostatin(ES)proteins in 255 specimens resected from NSCLC patients,using immune histochemistry(IHC).We then evaluated the relationships between the expression of the three proteins and clinical characteristics such as stage,histological type,differentiation,gender,tobacco use,and age.According to the value of VEGF/ES,we divided the cohort into angiogenesis-promoting group A,angiogenesis-inhibiting group A,and balance group A.The survival differences in the three groups were evaluated to determine the prognostic value of VEGF/ES.Similarly,we tested the prognostic value of VEGFR2/ES.Results VEGF-positive expression was observed in 93 patients(36.4%).VEGF expression was not correlated with the clinical characteristics.VEGFR2-positive expression was observed in 103 patients(40.4%).The expression of VEGFR2 was correlated with the clinical stage(χ^(2)=21.414,P=0.045)and histological type(χ^(2)=26.911,P=0.008).ES-positive expression was observed in 140 patients(54.9%).The expression of ES was correlated with the clinical stage(χ^(2)=26.504,P=0.009).When evaluating the prognostic values of VEGF/ES and VEGFR2/ES,the prognosis of the angiogenesis balance group was similar to that of the angiogenesis-inhibiting group.The minimum survival time was observed in the angiogenesis-promoting group.Conclusion VEGF/ES and VEGFR2/ES in resected tumors have prognostic value in postoperative NSCLC patients.The survival time of the population with predominant angiogenic factors was short. 展开更多
关键词 non-small cell lung cancer(NSCLC) angiogenesis clinical characteristics PROGNOSIS
下载PDF
Investigation of therapeutic modalities of G719X, an uncommon mutation in the EGFR gene in non-small cell lung cancer 被引量:1
4
作者 Hua Zheng Yuan Gao +7 位作者 Zan Liu Zhe Qian tongmei zhang Jie Li Hongmei zhang Qunhui Wang Fanbin Hu Baolan Li 《Oncology and Translational Medicine》 2019年第2期91-97,共7页
Objective G719 X is the most frequently seen uncommon mutation of the epidermal growth factor receptor(EGFR) gene, which is a point mutation at exon 18 with three common subtypes, G719 A/G719 C/G719 S. This study expl... Objective G719 X is the most frequently seen uncommon mutation of the epidermal growth factor receptor(EGFR) gene, which is a point mutation at exon 18 with three common subtypes, G719 A/G719 C/G719 S. This study explored the clinicopathological characteristics of the G719 X mutation and investigated the efficacy of EGFR-tyrosine kinase inhibitor(TKI) treatment and chemotherapy in patients with the G719 X mutation; the survival rate after these different treatment modalities were then analyzed in order to provide evidence for clinical treatment.Methods Clinical data of 41 patients with the G719 X mutation admitted in the Beijing Chest Hospital, Capital Medical University from September 2014 to July 2018, were collected and the EGFR mutations were detected by amplification refractory mutation system-polymerase chain reaction(ARMS-PCR). The clinicopathological characteristics of the G719 X mutation were analyzed, and the relationship among the G719 X mutation, the efficacy of different treatment modalities, and the progression-free survival(PFS) was analyzed. Results Of the 41 cases, 24(58.5%) were G719 X single mutations and 17(41.5%) were compound mutations, including G719 X/S768 I, G719 X/L861 Q, G719 X/19 del, and G719 X/c-Met compound mutation. The objective response rate(ORR) of first-line EGFR-TKI therapy was 50%(6/12), the disease control rate(DCR) was 83.3%(10/12), and the median PFS(mPFS) was 9 months. After resistance to EGFR-TKI in the previous treatment, the ORR(71.4%, 5/7) and DCR(100%, 7/7) were still high following EGFR-TKIs, by an mPFS of 8 months. The ORR of chemotherapy was 33.3%(2/6), the DCR was 100%(6/6), and the mPFS was 6 months. Conclusion G719 X is an uncommon mutation of the EGFR gene and is sensitive to many EGFR-TKIs. It can be treated with the second-or third-generation EGFR-TKIs after resistance to the first-generation EGFR-TKIs. G719 X mutation also showed favorable effect to chemotherapy. 展开更多
关键词 LUNG NEOPLASMS EGFR UNCOMMON MUTATION G719X TARGET therapy
下载PDF
VGLUT3 neurons in median raphe control the efficacy of spatial memory retrieval via ETV4 regulation of VGLUT3 transcription 被引量:2
5
作者 Aodi He Chen zhang +9 位作者 Xiao Ke Yao Yi Quntao Yu tongmei zhang Hongyan Yu Huiyun Du Hao Li Qing Tian Ling-Qiang Zhu Youming Lu 《Science China(Life Sciences)》 SCIE CAS CSCD 2022年第8期1590-1607,共18页
The raphe nucleus is critical for feeding, rewarding and memory. However, how the heterogenous raphe neurons are molecularly and structurally organized to engage their divergent functions remains unknown. Here, we gen... The raphe nucleus is critical for feeding, rewarding and memory. However, how the heterogenous raphe neurons are molecularly and structurally organized to engage their divergent functions remains unknown. Here, we genetically target a subset of neurons expressing VGLUT3. VGLUT3 neurons control the efficacy of spatial memory retrieval by synapsing directly with parvalbumin-expressing GABA interneurons(PGIs) in the dentate gyrus. In a mouse model of Alzheimer's disease(AD mice),VGLUT3→PGIs synaptic transmission is impaired by ETV4 inhibition of VGLUT3 transcription. ETV4 binds to a promoter region of VGLUT3 and activates VGLUT3 transcription in VGLUT3 neurons. Strengthening VGLUT3→PGIs synaptic transmission by ETV4 activation of VGLUT3 transcription upscales the efficacy of spatial memory retrieval in AD mice. This study reports a novel circuit and molecular mechanism underlying the efficacy of spatial memory retrieval via ETV4 inhibition of VGLUT3 transcription and hence provides a promising target for therapeutic intervention of the disease progression. 展开更多
关键词 VGLUT3 median raphe nucleus parvalbumin-expressing GABA interneurons spatial memory retrieval ETV4 Alzheimer's disease
原文传递
PINK1-mediated Drp1^(S616) phosphorylation modulates synaptic development and plasticity via promoting mitochondrial fission 被引量:1
6
作者 Qingtao Gao Runyi Tian +20 位作者 Hailong Han Jesse Slone Caifang Wang Xiao Ke tongmei zhang Xiangyu Li Yuhong He Panlin Liao Fang Wang Ye Chen Shiqing Fu Kexuan zhang Fangfang Zeng Yingxuan Yang Zhuo Li Jieqiong Tan Jiada Li Youming Lu Taosheng Huang Zhonghua Hu Zhuohua zhang 《Signal Transduction and Targeted Therapy》 SCIE CSCD 2022年第5期1719-1734,共16页
Dynamic change of mitochondrial morphology and distribution along neuronal branches are essential for neural circuitry formation and synaptic efficacy.However,the underlying mechanism remains elusive.We show here that... Dynamic change of mitochondrial morphology and distribution along neuronal branches are essential for neural circuitry formation and synaptic efficacy.However,the underlying mechanism remains elusive.We show here that Pink1 knockout(KO)mice display defective dendritic spine maturation,reduced axonal synaptic vesicles,abnormal synaptic connection,and attenuated long-term synaptic potentiation(LTP).Drp1 activation via ^(S616) phosphorylation rescues deficits of spine maturation in Pink1 KO neurons. 展开更多
关键词 PLASTICITY ACTIVATION SYNAPTIC
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部